期刊文献+

血液透析红细胞生成素抵抗患者pro-hepcidin与炎性反应和铁代谢的关系 被引量:4

Association of pro-hepcidin with inflammation and iron metabolism in hemodialysis patientswith erythropoietin resistance
原文传递
导出
摘要 目的研究维持性血液透析(MHD)红细胞生成素(EPO)抵抗患者pro-hepcidin与炎性反应和铁代谢的关系。方法40例MHD患者为研究对象,其中20例EPO低反应和20例EPO正常反应。20例健康体检者为对照组。检测参试者的血红细胞计数(RBC)、血红蛋白(Hb)、网织红细胞计数(Ret)、红细胞比容(Hct)、血清铁蛋白(sF)、转铁蛋白(TF)、血清铁和总铁结合力、转铁蛋白饱和度(TSAT)(TSAT=血清铁/总铁结合力)、血清pro-hepcidin、血清超敏c反应蛋白(hs.CRP),并比较组间差异。Pearson相关法分析pro-hepcidin的影响因素。ROC曲线预测pro-hepcidin对EPO抵抗的价值。结果MHD患者sF、血清pro-hepcidin、hs-CRP显著高于健康对照者(P〈0.01),TF显著低于健康对照者(P〈0.05)。EPO抵抗患者血清铁蛋白、血清pro-hepcidin、hs.CRP明显高于反应正常的患者(P〈0.01)。Pearson相关分析显示MHDEPO抵抗患者血清pro-hepcidin水平与血清铁蛋白(r=0.843,P=0.000)和hs-CRP(r=0.695,P=0.001)呈正相关。预测EPO抵抗的ROC曲线显示,pro-hepcidin、SF、hs-CRP曲线下面积分别为0.713、0.769和0.958。结论EPO抵抗与炎性反应和铁代谢相关。血清pro-hepcidin、SF、hs.CRP有可能成为EPO抵抗的标志。 Objective To examine the association of pro-hepcidin with iron metabolism and inflammation in maintenance hemodialysis (MHD) patients with erythropoietin (EPO) resistance. Methods Forty MHD patients and twenty healthy controls were enrolled in the study. Among MHD patients, 20 were hyporesponsive to EPO therapy and 20 were normal responsive to EPO therapy. Complete blood red cell count (RBC), Hb concentration, hematocrit (Hct), reticulocyte count (Ret), and serum ferritin (SF), serum iron (Fe), total ironbinding capacity (TIBC), saturation rate of transferrin (TSAT), transferrin (TF), hyper-sensitive C-reactive protein (hs-CRP), pro-hepcidin were measured in all the patients and controls. Differences were compared between groups. Influencing factors were analyzed by Pearson correlation. Predicting value of pro-hepcidin was investigated by ROC curve. Results Serum levels of SF, pro-hepcidin and hs-CRP were significantly higher in MHD patients than those in healthy controls (P〈O.O1), while serum TF was lower in MHD patients (P〈O.05). Serum levels of SF, pro-hepcidin and hs-CRP were significantly higher in EPO resistant patients as compared to normal responsive eases (P〈O.01). Serum pro-hepcidin level was positively correlated with SF (r=0.843, P=0.000) and hs-CRP (r=0.695, P= 0.001). In predicting EPO resistance, area under ROC curve of pro-hepcidin, SF and hs-CRP was 0.713, 0.769 and 0.958 respectively. Conclusions EPO resistance is correlated with inflammation and iron metabolism. Serum pro-hepcidin, SF and hs-CRP may be used as markers of EPO resistance in MHD patients.
出处 《中华肾脏病杂志》 CAS CSCD 北大核心 2012年第10期752-756,共5页 Chinese Journal of Nephrology
关键词 血液透析 红细胞生成素 C反应蛋白质 pro-hepcidin 血清铁蛋白 Hemodialysis I Erythropoietin C reactive proteins Pro-hepcidin Ferritin
  • 相关文献

参考文献16

  • 1Shinzato S, Abe K, Furusu A, et al. Serum pro-hepcidin level and iron homeostasis in japanese dialysis patients with Erythropoietin (EPO)-resistant anemia. Med Sci Monit, 2008, 14: 431-437.
  • 2Park CH, Valore EV, Waring AJ, et al. Hepcidin, a urinary antimierobial peptide synthesized in the liver. J Biol Chem, 2001, 276: 7806-7810.
  • 3Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest, 2004, 113: 1271-1276.
  • 4Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest, 2002, 110: 1037- 1044.
  • 5Macdougall IC, Cooper AC. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant, 2002, 17 Suppl 11: 39-43.
  • 6Cooper AC, Breen CP, Vyas B, et al. Poor response to recombinant erythropoietin is associated with loss of T- lymphocyte CD28 expression and altered interleukin- 10 production. Nephrol Dial Transplant, 2003, 18: 133-140.
  • 7Drtleke T. Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant, 2001, 16 Suppl 7: S25-S28.
  • 8Theurl I, Mattle V, Seifert M, et al. Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease. Blood, 2006, 107: 4142-4148.
  • 9Papanikolaou G, Tzilianos M, Christakis JI, et al. Hepcidin in iron overload disorders. Blood, 2005, 105: 4103-4105.
  • 10Hsu SP, Chiang CK, Chien CT, et al. Plasma prohepcidin positively correlates with hemat0crit in chronic hemodialysis patients. Blood Purif, 2006, 24: 311-316.

同被引文献28

  • 1KDOQI, National Kidney Founclation. KDOQI clinical practice guidelines and clinical practice recommendations for Anemia in chro- nic kidney Disease[J]. Am J Kidney Dis, 2006, 47 (5 Suppl 3) : S11-S15.
  • 2Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes [J]. Kidney Int, 2008, 74(6) : 791-798.
  • 3Erkmen Uyar M, Toprak SK, Saglam H, et al. rHuEPO hyporespons- iveness and related high dosages are associated with hyperviscosity in maintenance hemodialysis patients [ J ]. Scientific World Journal, 2013, 2013 : 792698.
  • 4Shinzato T, Abe K, Furusu A, et al. Serum pro-hepcidin level and i- ron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia [ J ]. Med Sci Monit, 2008, 14 ( 9 ) :CR431-437.
  • 5Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease [J]. J Am Soc Nephrol, 2006, 17(10) : 2937-2944.
  • 6Verga Falzacappa MV, Vujic Spasic M, Kessler R, et al. STA33 me- diates hepatic hepcidin expression and its inflammatory stimulation [J]. Blood, 2007, 109(1): 353-358.
  • 7Ashby DR, Gale DP, Busbridge M, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease [ J ]. Kidney Int, 2009, 75(9): 976-981.
  • 8Elliott J, Mishler D, Agarwal R. Hyporesponsiveness to erythropoie- tin: causes and management[J]. Adv Chronic Kidney Dis, 2009, 16(2) : 94-100.
  • 9Stein BL.The anemia of inflammation[J].J Clin Rheumatol,2012,18(8):4342-4374.
  • 10Vermeulen E,Vermeersch P.Hepcidin as a biomarker for the diagnosis of Iron metabolism disorders:a review[J].Acta Clin Belg,2012,67(3):190-197.

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部